Verseon was founded in 2002. Its proprietary drug discovery platform, developed entirely in-house, is the product of over ten years of research and development. The company’s platform is the first systematic, computationally-driven solution to achieve the molecular modelling accuracy necessary for rapid and cost-effective drug discovery.

Verseon plans to use its platform to establish a diversified discovery pipeline across multiple disease areas. Current drug programs include anticoagulation, diabetic macular edema, and oncology (solid tumors).

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods


Drug Programs

Three different therapeutic areas, all with unmet (or poorly met) medical needs